rs121909345
Positions:
Variant summary
Our verdict is Likely benign. Variant got -5 ACMG points: 0P and 5B. BP4BS2
The NM_004082.5(DCTN1):c.3302G>A(p.Arg1101Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000174 in 1,613,272 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000017 ( 0 hom. )
Consequence
DCTN1
NM_004082.5 missense
NM_004082.5 missense
Scores
6
13
Clinical Significance
Conservation
PhyloP100: 2.73
Genes affected
DCTN1 (HGNC:2711): (dynactin subunit 1) This gene encodes the largest subunit of dynactin, a macromolecular complex consisting of 10 subunits ranging in size from 22 to 150 kD. Dynactin binds to both microtubules and cytoplasmic dynein. Dynactin is involved in a diverse array of cellular functions, including ER-to-Golgi transport, the centripetal movement of lysosomes and endosomes, spindle formation, chromosome movement, nuclear positioning, and axonogenesis. This subunit interacts with dynein intermediate chain by its domains directly binding to dynein and binds to microtubules via a highly conserved glycine-rich cytoskeleton-associated protein (CAP-Gly) domain in its N-terminus. Alternative splicing of this gene results in multiple transcript variants encoding distinct isoforms. Mutations in this gene cause distal hereditary motor neuronopathy type VIIB (HMN7B) which is also known as distal spinal and bulbar muscular atrophy (dSBMA). [provided by RefSeq, Oct 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -5 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.29399675).
BS2
High AC in GnomAdExome4 at 25 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DCTN1 | NM_004082.5 | c.3302G>A | p.Arg1101Lys | missense_variant | 28/32 | ENST00000628224.3 | NP_004073.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DCTN1 | ENST00000628224.3 | c.3302G>A | p.Arg1101Lys | missense_variant | 28/32 | 5 | NM_004082.5 | ENSP00000487279.2 | ||
ENSG00000264324 | ENST00000451608.2 | n.41G>A | non_coding_transcript_exon_variant | 1/39 | 5 | ENSP00000416453.2 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152182Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
3
AN:
152182
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000281 AC: 7AN: 249326Hom.: 0 AF XY: 0.0000297 AC XY: 4AN XY: 134758
GnomAD3 exomes
AF:
AC:
7
AN:
249326
Hom.:
AF XY:
AC XY:
4
AN XY:
134758
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000171 AC: 25AN: 1461090Hom.: 0 Cov.: 32 AF XY: 0.0000179 AC XY: 13AN XY: 726730
GnomAD4 exome
AF:
AC:
25
AN:
1461090
Hom.:
Cov.:
32
AF XY:
AC XY:
13
AN XY:
726730
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152182Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74350
GnomAD4 genome
AF:
AC:
3
AN:
152182
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74350
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
5
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:4Other:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jul 18, 2024 | Variant summary: DCTN1 c.3302G>A (p.Arg1101Lys) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 2.8e-05 in 249326 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.3302G>A has been reported in the literature as heterozygous genotype in individuals affected with DCTN1-Related amyotrophic lateral sclerosis and frontotemporal dementia (FTD) in two siblings in one family respectively (Munch_2005). These report(s) do not provide unequivocal conclusions about association of the variant with DCTN1-Related Disorders. At least one publication reports experimental evidence evaluating an impact on protein function, however, does not allow convincing conclusions about the variant effect (Stockmann_2013). The following publications have been ascertained in the context of this evaluation (PMID: 16240349, 23143281). ClinVar contains an entry for this variant (Variation ID: 8405). Based on the evidence outlined above, the variant was classified as uncertain significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 03, 2021 | The p.R1101K variant (also known as c.3302G>A), located in coding exon 28 of the DCTN1 gene, results from a G to A substitution at nucleotide position 3302. The arginine at codon 1101 is replaced by lysine, an amino acid with highly similar properties. This variant was identified in the heterozygous state in a pair of siblings, one of whom had amyotrophic lateral sclerosis (ALS) and one of whom had frontotemporal dementia (FTD) (Münch C et al. Ann Neurol, 2005 Nov;58:777-80). In vitro experimental studies show that this alteration does not significantly impact protein function (Dixit R et al. J Biol Chem, 2008 Nov;283:33611-9; Stockmann M et al. J Neural Transm (Vienna), 2013 May;120:785-98). This amino acid position is well conserved in available vertebrate species; however, lysine is the reference amino acid in other vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
Neuronopathy, distal hereditary motor, type 7B;C1862939:Amyotrophic lateral sclerosis type 1;C1868594:Perry syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 17, 2023 | This sequence change replaces arginine, which is basic and polar, with lysine, which is basic and polar, at codon 1101 of the DCTN1 protein (p.Arg1101Lys). This variant is present in population databases (rs121909345, gnomAD 0.006%). This missense change has been observed in individual(s) with amyotrophic lateral sclerosis and frontotemporal dementia (PMID: 16240349). ClinVar contains an entry for this variant (Variation ID: 8405). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DCTN1 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change does not substantially affect DCTN1 function (PMID: 18812314, 23143281). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Perry syndrome Uncertain:1
Uncertain significance, no assertion criteria provided | literature only | Inherited Neuropathy Consortium Ii, University Of Miami | Jan 06, 2016 | - - |
Amyotrophic lateral sclerosis, susceptibility to Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Nov 01, 2005 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
T;.;T;.;.;.;T;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D;.;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
N;.;.;.;.;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;.;.;N;N;N;N
REVEL
Uncertain
Sift
Benign
T;T;.;.;T;T;T;T
Sift4G
Benign
T;T;T;T;T;T;T;T
Polyphen
B;.;.;B;.;.;.;.
Vest4
MutPred
Gain of ubiquitination at R1101 (P = 0.0162);.;.;.;.;.;.;.;
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at